Evidence map›Paper›PMID 36224722›Full record

ArticleCancer biology & therapy2022

Exosomal epidermal growth factor receptor is involved in HPV-16 E7-induced epithelial-mesenchymal transition of non-small cell lung cancer cells: A driver of signaling in vivo

Zhiyuan Zhou, Xiaofeng Wu, Riming Zhan, Xiangyong Li, Dazhao Cheng, Li Chen, Tianyu Wang, Hua Yu, Guihong Zhang, Xudong Tang

Open access · goldAbstract read
In one paragraph

Article in Cancer biology & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhiyuan ZhouInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Xiaofeng WuInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Riming ZhanInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Xiangyong LiInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Dazhao ChengInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Li ChenInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Tianyu WangInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Hua YuInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Guihong ZhangInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Xudong TangInstitute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.ORCID 0000-0002-3725-689X
Guangdong Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous studies have demonstrated that human papillomavirus (HPV)-16 E7 oncoprotein promoted epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells. Moreover, recent studies have found that exosomes can mediate EMT of NSCLC cells and epidermal growth factor receptor (EGFR) is related to the progression of NSCLC. Here, we further investigated the role of exosomal EGFR in HPV-16 E7-induced EMT of NSCLC cells. Our results showed that the exosomes derived from the stable HPV-16 E7-overexpressing A549 and NCI-H460 NSCLC cells (E7 Exo) significantly increased migration, invasion, and proliferation abilities of NSCLC cells as compared with the exosomes derived from empty vector-infected NSCLC cells (ev Exo). Moreover, both

Indexed as

Carcinoma, Non-Small-Cell LungExosomesLung NeoplasmsMicroRNAsPapillomavirus InfectionsCell Line, TumorEpithelial-Mesenchymal TransitionErbB ReceptorsHuman papillomavirus 16HumansPapillomavirus E7 ProteinsErbB ReceptorsMicroRNAsPapillomavirus E7 ProteinsEGFREMTExosomesHPV-16 E7NSCLC

Identifiers

PMID36224722
PMCPMC9559043
OpenAlexW4306156038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.